What's New in In Vivo CAR T?

As the first installment in the 2026 Johnson&Johnson and Legend CAR T Series, join Dr. Joy Ho and Dr. Marco Davila as they explore the latest advances in in vivo CAR T cell therapy, offering insights from both clinical and translational research perspectives.

Learning Objectives:
1. Identify the rationale for in vivo CAR-T therapy in multiple myeloma
2. Describe the basic mechanisms underlying lentiviral in vivo CAR-T in myeloma
3. Review early clinical data, including key parameters used to evaluate safety and efficacy
4. Discuss the practical implications and evolving clinical challenges in delivering in vivo CAR-T therapy for myeloma

Speakers:
1. Phoebe Joy Ho, MD: Royal Prince Alfred Hospital.
2. Marco Davila, MD, PhD: Roswell Park Comprehensive Cancer Center

Thank you to Johnson & Johnson and Legend Biotech for their generous support of this webinar series.